ExecutiveOrdersEO
EO 14336Executive OrderTrump 47 · R Quiet signal

Executive Order 14336

Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve

This Executive Order directs the Department of Health and Human Services to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with a 6-month supply of APIs for approximately 26 critical drugs, prioritizing domestic manufacturing. It also requires updating the essential medicines list and planning a second repository, while criticizing the prior administration for failing to advance domestic pharmaceutical production.

Federal Register Open PDF 90 FR 40223

Impact dates

  1. 7d ago

    Proposal and cost estimate for second SAPIR repository due

  2. ASPR readies SAPIR repository to receive APIs

  3. ASPR provides updated essential medicines list and expansion plan

  4. ASPR develops list of ~26 critical drugs and fund accounting

  5. Place APIs in SAPIR within 30 days of repository certification

Market exposure

Policy exposure mapping — not investment advice. Illustrative public companies are incomplete and not recommendations.

Sectors

PharmaChemicals

Mechanisms

ProcurementSubsidy / incentive

Role pressure

  • ProtectiveDomestic producer — Government procurement preference and stockpiling demand incentivize domestic API manufacturing investment
  • AdverseImporter — Domestic preference for SAPIR procurement reduces expected foreign API market share for reserve contracts; existing 90% foreign API dominance faces policy headwinds
  • MixedDownstream manufacturer — Domestic API availability could reduce supply risk but may face higher costs or limited initial capacity versus established foreign sources

Geographies

USCNINOTHER

Exposure dates

  • — Place APIs in SAPIR within 30 days of repository certification
  • — ASPR provides updated essential medicines list and expansion plan
  • — ASPR readies SAPIR repository to receive APIs
  • — Proposal and cost estimate for second SAPIR repository due

Illustrative public companies

Curated watchlist matches by sector/role — incomplete; not a recommendation.

MMM3MALBAlbemarleBASFYBASFCTVACortevaDOWDowDDDuPontLLYEli LillyJNJJohnson & JohnsonLYBLyondellBasellMRKMerckNVSNovartisPFEPfizerSQMSQM

Confidence: medium · Policy alerts

Key directives

  • ASPR shall develop list of ~26 critical drugs and fund accounting within 30 days
  • ASPR shall ready SAPIR repository within 120 days subject to fund availability
  • ASPR shall obtain 6-month supply of APIs with domestic preference, place within 30 days of repository certification
  • ASPR shall update essential medicines list and provide expansion plan within 90 days
  • Plan must include proposal and cost estimate for second repository within 1 year
  • OMB shall assist HHS Secretary in repurposing available funds

Who is ordered

Timeline

Immediate

  • ASPR to develop list of ~26 critical drugs and fund accounting (30 days)
  • OMB assistance to HHS Secretary for fund repurposing

Near term (90d)

  • ASPR to ready SAPIR repository for receiving APIs (120 days)
  • ASPR to provide updated essential medicines list and expansion plan (90 days)
  • Plan proposal for second SAPIR repository within 1 year

Long term

  • Obtain and place 6-month supply of APIs in SAPIR (triggered by repository certification + 30 days)
  • Potential opening of second SAPIR repository (within 1 year)
  • Sustained domestic API production incentives through government procurement preference

Risks & tensions

  • Subject to availability of appropriations/funds — funding constraint may delay or weaken implementation
  • Domestic preference 'if possible' is vague; may not overcome cost/scale advantages of foreign API producers
  • Criticism of prior administration suggests political framing but operational continuity with EO 13944 framework
  • No specified enforcement if domestic manufacturers cannot meet demand or timeline
  • Concentration risk in single repository until second site established
Executive Order 14336: Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve · Executive Orders